[HTML][HTML] Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - Springer
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - JOURNAL OF …, 2022 - flore.unifi.it
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - JOURNAL OF …, 2022 - iris.unisr.it
Early use of high-efficacy disease‑modifying therapies makes the difference in people with
multiple sclerosis: an expert opinion IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore …
multiple sclerosis: an expert opinion IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, M Amato, D Centonze, P Gallo… - JOURNAL OF …, 2022 - art.torvergata.it
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
[HTML][HTML] Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - europepmc.org
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - search.proquest.com
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
[PDF][PDF] Early use of high‑efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo10… - Journal of …, 2022 - iris.unict.it
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - search.ebscohost.com
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze… - Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …